Observational study in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
47 authors.
Christos V ChalitsiosDepartment of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece.ORCID 0000-0002-0836-9385
Georgios MarkozannesDepartment of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece.ORCID 0000-0001-8481-579X
Elom K AglagoDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0002-0442-3284
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0001-5230-0652
Daniel D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia.ORCID 0000-0003-2225-6675
Peter T CampbellDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States.ORCID 0000-0002-5549-2036
Yin CaoDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, United States.ORCID 0000-0001-9835-7662
Andrew T ChanDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.ORCID 0000-0001-7284-6767
Niki DimouNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-1678-9328
David A DrewDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-8813-0816
Amy J FrenchDivision of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.ORCID 0009-0002-3258-3653
Peter GeorgesonColorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, Australia.ORCID 0000-0002-5096-4735
Marios GiannakisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.ORCID 0000-0001-9012-6982
Stephen B GruberDepartment of Medical Oncology and Therapeutics Research and Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, United States.ORCID 0000-0001-8656-7822
Marc J GunterDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Tabitha A HarrisonPublic Health Sciences Division, Seattle, WA, United States.ORCID 0000-0002-4173-7530
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany.ORCID 0000-0002-8307-3197
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.ORCID 0000-0002-4440-3368
Meredith A J HullarPublic Health Sciences Division, Seattle, WA, United States.ORCID 0000-0002-5322-9568
Jeroen R HuyghePublic Health Sciences Division, Seattle, WA, United States.ORCID 0000-0001-6027-9806
Brigid M LynchCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.ORCID 0000-0001-8060-547X
Victor MorenoUnit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0002-2818-5487
Neil MurphyNutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France.
Christina C NewtonDepartment of Population Science, American Cancer Society, Atlanta, GA, United States.ORCID 0000-0003-1471-5608
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-0943-7407
Mireia Obón-SantacanaUnit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0003-4646-3513
Shuji OginoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, United States.ORCID 0000-0002-3909-2323
Conghui QuPublic Health Sciences Division, Seattle, WA, United States.
Stephanie L SchmitGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.ORCID 0000-0001-5931-1194
Robert S SteinfelderPublic Health Sciences Division, Seattle, WA, United States.ORCID 0000-0003-4204-8013
Claire E ThomasPublic Health Sciences Division, Seattle, WA, United States.ORCID 0000-0001-9515-3277
Amanda E TolandDepartments of Cancer Biology and Genetics, The Ohio State University, Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States.ORCID 0000-0002-0271-1792
Quang M TrinhOntario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000-0002-3602-2290
Tomotaka UgaiDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, United States.ORCID 0000-0003-0182-5269
Caroline Y UmDepartment of Population Science, American Cancer Society, Atlanta, GA, United States.ORCID 0000-0001-5449-6230
Bethany Van GuelpenDepartment of Diagnostics and Intervention, Oncology Unit, Umeå University, Umeå, Sweden.ORCID 0000-0002-9692-101X
Syed H ZaidiOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Robert E SchoenDepartment of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.ORCID 0000-0001-7153-2766
Michael O WoodsDiscipline of Genetics, Memorial University of Newfoundland, St John's, Canada.ORCID 0000-0001-8180-418X
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany.ORCID 0000-0002-6129-1572
Laura AndresonHealth Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-6106-5073
Ulrike PetersPublic Health Sciences Division, Seattle, WA, United States.
Amanda I PhippsPublic Health Sciences Division, Seattle, WA, United States.ORCID 0009-0002-4864-8351
Konstantinos K TsilidisDepartment of Hygiene and Epidemiology, University of Ioannina, Ioannina, Greece.ORCID 0000-0002-8452-8472
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Molecular pathological epidemiology of colorectal cancerU01CA137088 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2009 to 2018
$21.8M
Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7M
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression: A double-blind randomized controlled trialR01CA281759 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Neeraj Agarwal, Adriana Coletta · 2023 to 2026
$2.7M
Molecular Correlates of Outcomes in Clinical Trials of Colon CancerR01CA176272 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHAN, ANDREW T, NEWCOMB, POLLY A · 2013 to 2017
$2.5M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
Center for Inherited Disease Research (CIDR) HHSN268201700006I and HHSN268201200008IGECCO: National Cancer Institute (NCI), National Institutes of Health (NIH), US Department of Health and Human Services U01 CA137088, R01 CA176272NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA176272NCI NIH HHS R01 CA281759NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA272529NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INHLBI NIH HHS HHSN268201700006CNIH HHS S10 OD028685ORIP NIH HHS S10OD028685World Health Organization 001
6 · The paper itself
Abstract
backgroundPhysical activity is associated with lower colorectal cancer (CRC) risk, but its association with molecular subtypes defined by genetic and epigenetic alterations of the disease is unclear. Such information may enhance the understanding of the mechanisms related to the benefits of physical activity.
methodsPooled observational (cases: n = 5386; controls: n = 6798; studies n = 5) and genome-wide association data (cases: n = 8178; controls: n = 10 472; studies n = 5) were used. We used multivariable logistic regression models and Mendelian randomization to assess the association between physical activity and the risk of CRC subtypes defined by individual tumor markers (and marker combinations), namely microsatellite instability status, CpG island methylator phenotype status, and BRAF and KRAS mutations. We used case-only analysis to test for differences between molecular subtypes. We applied Bonferroni correction to account for multiple tests.
resultsIn the pooled observational analysis, higher levels of physical activity were associated with lower CRC risk (Obs-per 1SD, odds ratio [OR] = 0.94, 95% confidence interval [CI] = 0.90 to 0.97), with an association that was stronger in males (Obs-per 1SD, OR = 0.91, 95% CI = 0.87 to 0.96) than in females (Obs-per 1SD, OR = 0.97, 95% CI = 0.91 to 1.03; Pinteraction = .04). Higher physical activity was associated with a lower risk of CRC across all molecular subtypes, especially in males. There was no difference in the associations by subtypes by pooled observational or Mendelian randomization analyses. The findings did not differ by study design, anatomical site, and early or late age onset of CRC.
conclusionsOur findings suggest that physical activity is not differentially associated with the 4 major molecular subtypes involved in colorectal carcinogenesis, indicating that its benefits extend broadly across colorectal cancer pathogenesis.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Physical activity and molecular subtypes of colorectal cancer: a pooled observational analysis and Mendelian randomization study. · full record | OpenQuestion